Induction of Cross-protective Antibodies for Serogroup 33 by Pneumococcal Conjugate Vaccines (Group 33/PCVs)

The University of Alabama at Birmingham

Status and phase: Not yet enrolling; Phase 4

Conditions: Vaccine; Pneumococcal Disease

Treatments: Biological: Pneumococcal Vaccine

Study type: Interventional

Funder types: Other; Industry

Identifiers

NCT07135453

MISP102547 (Other Grant/Funding Number)

IRB300008528(000544386)

Details and patient eligibility

About

The goal of this study is to learn whether different types of vaccines to prevent bacterial infections are able to effectively create antibodies that defend against certain types of bacteria.

We will give two different types of vaccine and evaluate the effectiveness of antibodies produced by each vaccine in killing bacteria.

Enrollment: 70 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: Accepts Healthy Volunteers

Inclusion criteria

• Healthy adult

Exclusion criteria

• No prior history of pneumococcal vaccination
• No immunosuppressing medications or chronic diseases that affect immune function

Trial design

Primary purpose: Basic Science

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

70 participants in 2 patient groups

PCV20

Experimental group

Description:

Will receive PCV20

Treatment:

Biological: Pneumococcal Vaccine

PCV21

Experimental group

Description:

Will receive PCV21

Treatment:

Biological: Pneumococcal Vaccine